HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Achim A Jungbluth Selected Research

Ipilimumab

1/2013A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.
3/2012Immunologic correlates of the abscopal effect in a patient with melanoma.
10/2011Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
1/2010Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
12/2008CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Achim A Jungbluth Research Topics

Disease

125Neoplasms (Cancer)
05/2024 - 02/2002
56Testicular Neoplasms (Testicular Cancer)
05/2022 - 02/2002
44Melanoma (Melanoma, Malignant)
11/2023 - 06/2002
20Carcinoma (Carcinomatosis)
12/2021 - 06/2002
14Breast Neoplasms (Breast Cancer)
05/2024 - 03/2003
12Sarcoma (Soft Tissue Sarcoma)
02/2022 - 06/2002
7Prostatic Neoplasms (Prostate Cancer)
11/2013 - 04/2007
7Neoplasm Metastasis (Metastasis)
08/2013 - 10/2002
6Multiple Myeloma
01/2019 - 07/2005
5Squamous Cell Carcinoma of Head and Neck
05/2022 - 05/2011
5Leiomyosarcoma
12/2021 - 01/2018
5Lung Neoplasms (Lung Cancer)
07/2015 - 03/2003
5Ovarian Neoplasms (Ovarian Cancer)
11/2013 - 09/2003
4Renal Cell Carcinoma (Grawitz Tumor)
10/2016 - 06/2002
4Glioma (Gliomas)
03/2011 - 03/2002
4Esophageal Neoplasms (Esophageal Cancer)
11/2008 - 03/2003
4Ovarian Epithelial Carcinoma
05/2008 - 09/2003
3Urinary Bladder Neoplasms (Bladder Cancer)
10/2022 - 12/2003
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 02/2007
3Colorectal Neoplasms (Colorectal Cancer)
12/2021 - 08/2011
3Nevus (Nevi)
01/2020 - 10/2002
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2018 - 03/2004
3Endometrioid Carcinoma
09/2017 - 01/2005
3Synovial Sarcoma (Synovioma)
01/2013 - 02/2002
3Colonic Neoplasms (Colon Cancer)
12/2011 - 07/2002
3Stomach Neoplasms (Stomach Cancer)
11/2006 - 11/2004
2Thyroid Neoplasms (Thyroid Cancer)
01/2021 - 12/2017
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
12/2020 - 10/2007
2Adenocarcinoma of Lung
01/2018 - 02/2007
2Neuroblastoma
01/2018 - 04/2005
2Thyroid Diseases (Thyroid Disease)
12/2017 - 10/2011
2Merkel Cell Carcinoma
01/2017 - 08/2015
2Endometrial Neoplasms (Endometrial Cancer)
01/2016 - 01/2005
2Disease Progression
11/2013 - 01/2013
2Hypersensitivity (Allergy)
01/2013 - 07/2004
2Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
01/2013 - 09/2012
2Injection Site Reaction
12/2012 - 11/2008

Drug/Important Bio-Agent (IBA)

78AntigensIBA
11/2023 - 02/2002
38Proteins (Proteins, Gene)FDA Link
12/2021 - 06/2002
23Monoclonal AntibodiesIBA
01/2022 - 02/2002
23VaccinesIBA
11/2019 - 10/2003
19Messenger RNA (mRNA)IBA
11/2019 - 06/2002
16AntibodiesIBA
01/2020 - 03/2002
13Neoplasm Antigens (Tumor Antigens)IBA
01/2019 - 07/2002
11Differentiation AntigensIBA
03/2016 - 10/2002
10RNA (Ribonucleic Acid)IBA
01/2021 - 10/2004
9Peptides (Polypeptides)IBA
05/2024 - 07/2007
9Cancer VaccinesIBA
04/2020 - 10/2002
8MART-1 AntigenIBA
01/2022 - 10/2002
7Biomarkers (Surrogate Marker)IBA
05/2024 - 02/2009
7DNA (Deoxyribonucleic Acid)IBA
01/2022 - 02/2014
7ParaffinIBA
01/2019 - 12/2003
6Indicators and Reagents (Reagents)IBA
01/2019 - 06/2002
6Monophenol Monooxygenase (Tyrosinase)IBA
03/2013 - 10/2002
5EnzymesIBA
05/2024 - 03/2004
5Phosphotransferases (Kinase)IBA
01/2018 - 02/2007
5IpilimumabIBA
01/2013 - 12/2008
5monoclonal antibody 806IBA
03/2007 - 03/2002
5ErbB Receptors (EGF Receptor)IBA
03/2007 - 01/2003
4Hormones (Hormone)IBA
05/2024 - 03/2004
4Estrogen ReceptorsIBA
01/2022 - 05/2006
4Formaldehyde (Formol)FDA Link
10/2019 - 01/2005
4Complementary DNA (cDNA)IBA
02/2008 - 07/2002
3DesminIBA
01/2021 - 01/2018
3Immune Checkpoint InhibitorsIBA
01/2021 - 01/2018
3Histones (Histone)IBA
10/2019 - 10/2002
3Progesterone Receptors (Progesterone Receptor)IBA
01/2018 - 08/2009
3arginine deiminaseIBA
12/2013 - 02/2012
3Monatide (IMS 3015)IBA
11/2013 - 05/2007
3Arginine (L-Arginine)FDA Link
04/2013 - 02/2012
3RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
09/2012 - 02/2002
3EpitopesIBA
04/2007 - 07/2004
3epidermal growth factor receptor VIIIIBA
02/2007 - 03/2002
2Cathepsin KIBA
01/2022 - 11/2019
2B7-H1 AntigenIBA
01/2021 - 01/2020
2Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
11/2020 - 07/2015
2Immunoglobulin G (IgG)IBA
01/2018 - 07/2002
2ChromatinIBA
03/2017 - 01/2017
2Coloring Agents (Dyes)IBA
12/2016 - 03/2005
2poly ICLCIBA
11/2013 - 12/2012
2Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA
04/2013 - 01/2013
2AutoantigensIBA
12/2012 - 01/2008
2Tumor Biomarkers (Tumor Markers)IBA
08/2012 - 02/2009
2pullulanIBA
02/2012 - 04/2007
2CholesterolIBA
02/2012 - 04/2007
2CTLA-4 AntigenIBA
10/2011 - 12/2008
2Prostate-Specific Antigen (Semenogelase)IBA
02/2009 - 04/2007
2Recombinant ProteinsIBA
11/2008 - 03/2004
2Temozolomide (Temodar)FDA LinkGeneric
05/2008 - 12/2003
2Glycoproteins (Glycoprotein)IBA
02/2008 - 01/2006
2Membrane Proteins (Integral Membrane Proteins)IBA
11/2007 - 01/2006
2Histocompatibility Antigens Class IIBA
11/2007 - 03/2007
2S100 Proteins (S 100 Protein)IBA
12/2003 - 10/2002

Therapy/Procedure

38Immunotherapy
10/2022 - 02/2002
28Therapeutics
05/2024 - 03/2002
9Drug Therapy (Chemotherapy)
11/2019 - 03/2004
3Stem Cell Transplantation
06/2014 - 02/2007
2Radioimmunotherapy
01/2018 - 12/2011
2Radiotherapy
04/2016 - 03/2012
2Hematopoietic Stem Cell Transplantation
06/2014 - 01/2013